Hims & Hers Health Inc. Class A (HIMS)
NYSE: HIMSHealth CareMedical/Nursing ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HIMS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.42B
- Forward P/E
- 48.67
- EPS (TTM)
- -$0.83
- Dividend yield
- None
- 52-week range
- 13.74 – 40.99
- Day range
- 14.51 – 15.96
- Volume / Avg
- 16.06M / 11.95M
- Beta
- —
- Shares outstanding
- 226.03M
52-week range
HIMS stock today
On Nov 20, HIMS ended the session at $14.60, shedding $1.42 (8.86%), versus the S&P 500's 3.70% decline. Shares are 64.4% below their 52-week high of $40.99, set on Dec 5, 2025 and 6.3% above the 52-week low of $13.74, near the bottom of the past year's range. HIMS is down 55.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.9%.
Hims & Hers Health has posted a net loss over the last twelve months (EPS of -$0.83), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Hims & Hers Health
Company profileHims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- CEO
- Mr. Andrew Dudum
- Headquarters
- San Francisco, CA
- Employees
- 2,442
- IPO year
- 2019
- Website
- hims.com
Financial highlights
Full financialsIn fiscal 2025, Hims & Hers Health generated $2.35 billion in revenue, up 59.0% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $128.4 million (+1.8% year over year), for a net margin of 5.5% versus a median of -12.2% in the prior 5 years. Gross margin was 73.8% (down from 79.5%) and operating margin 4.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.35B | $1.48B | $872.00M | $526.92M | $271.88M |
| Growth | +59.00% | +69.33% | +65.49% | +93.81% | +82.77% |
| Net income | $128.37M | $126.04M | $-23.55M | $-65.68M | $-107.66M |
| EPS (diluted) | $0.51 | $0.53 | $-0.11 | $-0.32 | $-0.58 |
Analyst forecast
ForecastConsensus (15 analysts)
hold
Avg. price target
$27.23+86.51%
- Strong buy 3
- Buy 1
- Hold 11
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $0.06 vs $0.07
- Surprise
- -14.29%
HIMS news
All HIMS news- Hims & Hers Launches Peptides+ to Expand Personalized Health CareNasdaqHIMS, ISRG, WST, GKOS
- Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?Nasdaq
- Why Is Hims Stock Crashing, and is it a Buying Opportunity?Nasdaq
- Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?Nasdaq
- HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss DrugsNasdaqLLY, HIMS, ISRG, GKOS
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffNasdaqHIMS, NVO, LLY, META
- Hims & Hers Q3 Earnings Miss Estimates, Gross Margin DownNasdaqHIMS, MMSI, OPK, GMED
- Five States Join FTC Lawsuit Against Hims & Hers Over Privacy And Billing PracticesNasdaq
Hims & Hers Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRVAPrivia Health Group Inc. | 25.05 | +1.46% | $3.20B | vs HIMS |
| AVAHAveanna Healthcare Holdings Inc. | 11.01 | +2.90% | $2.40B | vs HIMS |
| ADUSAddus HomeCare Corporation | 122.50 | +1.18% | $2.28B | vs HIMS |
| OPCHOption Care Health Inc. | 31.59 | -0.06% | $4.73B | vs HIMS |
| LFSTLifeStance Health Group Inc. | 13.82 | +3.60% | $5.25B | vs HIMS |
| USPHU.S. Physical Therapy Inc. | 95.93 | +1.71% | $1.43B | vs HIMS |
| WGSGeneDx Holdings Corp. Class A | 45.46 | -7.68% | $1.36B | vs HIMS |
| TDOCTeladoc Health Inc. | 7.45 | -4.36% | $1.36B | vs HIMS |
Indexes, lists and sector
Hims & Hers Health stock FAQ
What is Hims & Hers Health's stock price today?
HIMS last traded at $14.60 as of Nov 20, 4:00 PM EST, down 8.86% on the day. Prices are delayed at least 15 minutes.
Who is Hims & Hers Health's CEO?
Mr. Andrew Dudum is the chief executive officer of Hims & Hers Health Inc. Class A, which has about 2,442 employees.
What is the HIMS 52-week high?
The 52-week high for HIMS is $40.99 and the 52-week low is $13.74. The stock is currently 64.4% below its high.